



OPEN

SUBJECT AREAS:

MOLECULAR
NEUROSCIENCE

MECHANISMS OF DISEASE

Received
22 July 2013Accepted
3 September 2013Published
19 September 2013Correspondence and
requests for materials
should be addressed to
S.F.T.W. (stefan.
weiss@wits.ac.za)

Anti-LRP/LR specific antibody IgG1-iS18 and knock-down of LRP/LR by shRNAs rescue cells from A β ₄₂ induced cytotoxicity

Bianca Da Costa Dias¹, Katarina Jovanovic¹, Danielle Gonsalves¹, Kiashanee Moodley¹, Uwe Reusch², Stefan Knackmuss², Clement Penny³, Marc S. Weinberg⁴, Melvyn Little² & Stefan F. T. Weiss¹

¹School of Molecular and Cell Biology, University of the Witwatersrand, Private Bag 3, Wits 2050, Johannesburg, Republic of South Africa, ²Affimed Therapeutics AG, Technologiepark, Im Neuenheimer Feld 582, 69120 Heidelberg, Germany, ³Department of Internal Medicine, University of the Witwatersrand, 7 York Rd, Johannesburg, 2193 Parktown, Republic of South Africa, ⁴Antiviral Gene Therapy Research Unit (AGTRU), Department of Molecular Medicine & Haematology, School of Pathology, University of the Witwatersrand, Private Bag 3, Wits 2050, Johannesburg, Republic of South Africa.

Alzheimer's disease (AD) is characterized by neurofibrillary tangles, senile plaques and neuronal loss. Amyloid beta (A β) is proposed to elicit neuronal loss through cell surface receptors. As A β shares common binding partners with the 37 kDa/67 kDa laminin receptor (LRP/LR), we investigated whether these proteins interact and the pathological significance of this association. An LRP/LR-A β ₄₂ interaction was assessed by immunofluorescence microscopy and pull down assays. The cell biological effects were investigated by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and Bromodeoxyuridine assays. LRP/LR and A β ₄₂ co-localised on the cell surface and formed immobilized complexes suggesting an interaction. Antibody blockade by IgG1-iS18 and shRNA mediated down regulation of LRP/LR significantly enhanced cell viability and proliferation in cells co-treated with A β ₄₂ when compared to cells incubated with A β ₄₂ only. Results suggest that LRP/LR is implicated in A β ₄₂ mediated cytotoxicity and that anti-LRP/LR specific antibodies and shRNAs may serve as potential therapeutic tools for AD.

Neurodegenerative diseases represent the fourth major cause of global mortality after ischaemic heart disease, cerebrovascular disease and trachea, bronchus and lung cancers. Alzheimer's Disease (AD) is the predominant progressive dementing neurodegenerative disorder afflicting the elderly¹ and is characterized by "positive" and "negative" lesions including amyloid beta plaques, neurofibrillary tangles and neuronal, neuropil and synaptic loss respectively^{2,3}. Many of the neuronal perturbations in AD are attributable to and probably induced by the amyloid beta (A β) peptide². The A β fragment is derived from the transmembrane region of the Amyloid Precursor Protein (APP). Although A β is a normal physiological peptide, elevated concentrations of the peptide, which consequently results in the onslaught of AD, are generated either through the inappropriate favouring of the amyloidogenic processing of APP or a decline in A β clearance or degradation⁴. The amyloid plaques are predominantly composed of the A β ₄₂ isoform which has a higher aggregation propensity⁵ and neural toxicity⁶ than the 40 amino acid isoform (A β ₄₀) which predominates in non-diseased brains. However, the prevailing sentiment is that the plaques themselves are not the pathological agents but rather contribute to neural dysfunction through the distortion of neuronal morphology (within a 50 μ m radius^{7,8}) and by hampering neurotransmission⁹. Rather, it is the soluble A β oligomers which are deemed neurotoxic.

The proposed mechanisms whereby A β has been reported to impair neuronal function are numerous. A common thread in A β induced cytotoxicity and neuronal dysfunction is the requirement for an interaction between the neurotoxic peptide and cellular components, of greatest importance are the lipid membranes and cellular receptors¹⁰.

Owing to the hydrophobic nature of the peptide, A β may readily associate with and be subsequently incorporated into plasma^{11,12}, nucleosomal and lysosomal membranes. This may result in membrane structure distortion and the formation of ion-permissible (of particular concern is Ca²⁺) channels, the resultant ion influx may induce cytotoxicity^{13,14}.



Several of the factors thought to contribute to AD, namely oxidative stress, protein degradation, lipid oxidation and slowed signal transmission may be attributed to A β interaction with cell surface receptors^{15–17}. These include, but are not limited to, N-methyl-D-aspartate receptors (NMDAR), integrins (particularly $\alpha_5\beta_1$), insulin receptors, α -7 nicotinic acetylcholine receptors (α 7nAChR), the receptor for advanced glycation end products (RAGE), Ephrin-type B2 receptor (EphB2) and the cellular prion protein (PrP^c)^{1,10}. A β may thwart NMDAR activation and the resultant induction of long term potentiation (LTP) by desensitizing the receptor to synaptic glutamate^{10,18} or by prompting receptor internalization¹⁰. This in turn results in aberrant signaling cascades and ultimately results in synaptic dysfunction and neuronal death.

Although the association between A β and PrP^c has been one of mounting interest over the past decade, its biological influence remains to be definitively characterized. It has been suggested that PrP^c plays a role in mediating the devastating effects of A β oligomers particularly neuronal and synaptic toxicity and LTP impedance¹⁹ as well as stimulating pro-apoptotic signal transduction cascades²⁰. On the contrary a neuroprotective role for PrP^c has been proposed as the protein was reported to hinder β -secretase cleavage of APP²¹.

A receptor of noted physiological importance which binds to PrP^c and is implicated in PrP^c internalization is the 37 kDa/67 kDa laminin receptor (LRP/LR)²². This multifunctional protein is located in multiple cellular compartments namely the nucleus, cytosol and within the lipid raft domains of the plasma membrane^{23,24}. LRP/LR exhibits binding affinities for a multitude of cellular components including: extracellular matrix (ECM) molecules, laminin-1 being of greatest physiological relevance with regard to cellular adhesion, survival and migration as well as cytoskeletal, ribosomal and histone proteins and PrP^c^{23,24}. LRP/LR is also of pathological importance as the receptor has been shown to be central in prion protein uptake, propagation and progression of prion disorders^{25–27}. Furthermore, LRP/LR plays a central role in metastatic cancer and antibodies targeting the receptor have been reported to significantly impede adhesion and invasion of numerous cancer types, namely fibrosarcoma²⁸, lung, cervical, colon, prostate²⁹, breast and oesophageal cancer³⁰ as well as inhibit *in vitro* angiogenesis³¹.

As A β toxicity has been positioned to be mediated through its association with the lipid raft region of the plasma membrane and its interactions with plasma membrane anchored proteins, and LRP/LR shares mutual binding partners with A β (laminin³² and PrP^c), we aimed to examine whether LRP/LR and A β interact on the cell surface and to investigate whether LRP/LR plays a central role in A β induced cytotoxicity.

Results

LRP/LR co-localises with A β on the cell surface. Indirect immunofluorescence is regularly employed to provide a preliminary indication of potential interactions at the cell surface^{33,34}. Here too this methodology was employed to investigate whether endogenous LRP/LR and A β are located in close proximity on the cell surface, which would thereby indicate that an association between these proteins is conceivable. Co-localization of LRP/LR and A β was observed on the surface of non-permeabilized HEK293 and N2a cells (Fig. 1c and Fig. 1o, respectively). 2D cytofluorograms represent both green and red fluorescence and the resultant yellow diagonal (Fig. 1d and Fig. 1p) reveals that the fluorescence from both proteins is jointly distributed. These images, in addition to the highly positive Pearson's correlation coefficient (Table 1), verify that LRP/LR and A β co-localize on the cell surface. LRP/LR did not co-localize with the Very Late Antigen 6 (VLA6), a laminin binding integrin, (Fig. 1g and Fig. 1s). This was indicated by the 2D-cytofluorogram (Fig. 1h and Fig. 1t) as well as the very low Pearson's correlation coefficient (Table 1). VLA6 thereby served as the negative control²⁵.

Therefore, owing to the cell surface proximity of LRP/LR and A β , an association between these proteins is feasible.

Interaction of A β with LRP/LR. Although co-localisation studies between LRP/LR and A β proved the proximity of the proteins on the cell surface, this finding merely indicates that an interaction between these proteins is feasible. Therefore a pull down assay was performed to investigate definitively whether a stable interaction exists. Recombinantly expressed LRP::FLAG was immobilized on the anti-FLAG[®] M2 agarose beads, as highlighted by the red arrow (Fig. 2a and 2e) as it is present in the eluted sample. The identity of the band was further authenticated by immunoblotting (Fig. 2b). Co-incubation of anti-FLAG[®] M2 beads with LRP::FLAG containing cell lysate to which 100 ng/ml of synthetic A β ₄₂ was applied resulted in the immobilization of both proteins. The presence of A β ₄₂ in the eluted sample (Fig. 2a) was confirmed by equivalent polypeptide position in Fig. 2a lane 6 containing pure, synthetic A β ₄₂ (2 μ g). The presence of both proteins in eluted samples (Fig. 2a - lane 5) implies that an association exists. The relevant controls are shown in Fig. 2c–f.

IgG1-iS18 rescues cells from A β mediated cytotoxicity. A MTT cell viability assay was employed to assess the cytotoxicity of synthetic amyloid beta (A β ₄₂) at various concentrations on HEK293FT, N2a and SHSY5Y cells (Fig. 3 a–c). Exogenous application of 200 nM and 500 nM A β ₄₂ significantly reduced cell viability in HEK293 cells (Fig. 3a). Co-incubation of cells with 50 μ g/ml anti-LRP/LR specific antibody IgG1-iS18 and 500 nM A β ₄₂ significantly enhanced cell viability (Fig. 3a). Similar results, albeit at different A β ₄₂ concentrations were observed for SH-SY5Y (Fig. 3b) and N2A (Fig. 3c) cells. The decrease in cell viability observed in N2a cells (Fig. 3c) was shown to be as a result of hampered cellular proliferation (Fig. 3d). Protocatechuic acid (PCA) an apoptosis inducing agent was employed, at a concentration of 8 mM, as the positive control. Antibody, IgG1-iS18, treatment alone in the absence of A β does not significantly enhance cellular viability in all the model cell lines employed (Fig. S1), thereby negating the possibility that IgG1-iS18 non-specifically enhances cellular viability.

To confirm that LRP/LR plays a role in A β toxicity, and that the IgG1-iS18 effects observed are not owing to the possible lack of antibody specificity, RNA interference technology and more specifically short hairpin RNAs (shRNAs) were employed to down regulate LRP/LR. When compared to the shRNAsc control, shRNA1.1 transfection resulted in a 20.52% reduction in LRP/LR expression, whilst shRNA7.6 transfection produced a significant 67.46% reduction in LRP/LR expression levels (Fig. 4a and 4b). LRP/LR down regulation (mediated by the aforementioned shRNAs), in the presence of varying concentrations of exogenously administered A β ₄₂, resulted in a significant enhancement in cell viability (Fig. 4c) and cellular proliferation (Fig. 4d). These results are analogous to those obtained employing IgG1-iS18. No significant difference amongst untreated, mock transfected and shRNAsc transfected cells HEK293 cells was observed with regards to both cellular viability (Fig. S2a) and proliferation (Fig. S2b).

Discussion

LRP/LR and A β were demonstrated to share close cell surface proximity by indirect immunofluorescence microscopy (Fig. 1c and Fig. 1o) and these results were considered as a primary indication of a potential interaction between these proteins on the cell surface. However, supplementary systems are commonly required to verify the interaction proposed by immunofluorescence data.

In an attempt to confirm the proposed interaction between LRP/LR and the neurotoxic A β ₄₂ peptide, as revealed by co-localization results, pull down assays were performed. The presence of both proteins in the eluted sample suggests that an association between




Figure 1 | Cell surface co-localisation between LRP/LR with A β . (a) Endogenous cell surface LRP/LR and A β on HEK293 (upper panel) and N2a (lower panel) cells were indirectly immunolabelled. A β was indirectly detected using anti- β -amyloid (22–35) (Sigma) and anti-rabbit Alexafluor 633 antibodies (Fig. 1a, m). LRP/LR was detected employing anti-IgG1-iS18 (human) and anti-human-FITC (Cell lab) antibodies (Fig. 1b, f and Fig. 1n, r). Merged images (Fig. 1c, o) and 2D-cytofluorograms (Fig. 1d, p) (acquired using CellSens Software) verified the co-localization. The negative control, Very Late Antigen 6 (VLA6) was detected employing anti-VLA6 and anti-rabbit Alexafluor 633 antibodies (Fig. 1e, q). The merged images (Fig. 1g, s) and 2D-cytofluorograms (Fig. 1h, t) demonstrated that VLA6 and LRP/LR do not co-localize on the cell surface. Secondary antibody controls are shown in Fig. 1i–l and Fig. 1u–x. Fluorescence was detected and resultant images acquired using the Olympus IX71 Immunofluorescence Microscope and Analysis Get It Research Software. Scale bars are 10 μ m.

Table 1 Pearson's Correlation Co-efficient for LRP/LR, A β and VLA6 cell surface co-localization		
	HEK293	N2a
LRP/LR + A β	0.926	0.969
LRP/LR + VLA6	0.30	0.12

LRP and A β_{42} exists. However, the exclusivity of this interaction could not be verified owing to the presence of contaminant bands present within the eluted sample lane (Fig. 2a, lane 5). These polypeptides may represent numerous LRP ligands, possibly including laminin, PrP^c, actin, tubulin³⁵, heparin sulphate proteoglycans as well as ribosomal and histone components. The control shall be briefly discussed. Anti-FLAG[®] M2 agarose beads were subjected to incubation in the presence of lysis buffer (Fig. 2c) as well as cell-lysates




Figure 2 | LRP/LR as a potential A β -interacting protein. Pull down assays were employed using FLAG[®] Immunoprecipitation kit (Sigma Aldrich), to investigate the proteins detectable in unbound samples (lane 2), wash steps (lanes 3 and 4) and eluted samples (Fig. 2a–e: lane 5 and Fig. 2f: lane 6) and 2 μ g of synthetic A β ₄₂ (positive control) (Fig. 2a: lane 6 and Fig. 2f: lane 7). (a) Cell lysates containing recombinantly expressed LRP/LR::FLAG were co-incubated with exogenous A β . (b) Immunoblot employed to validate the position of LRP::FLAG (~38 kDa). Figures represent anti-FLAG[®] M2 beads incubated with (c) lysis buffer, (d) non-transfected HE293 cell lysates, (e) HEK293 cell lysates of cells transfected with pCIneo::FLAG as well as (f) pure synthetic A β ₄₂ in the absence of cell lysate. Samples were resolved on 16% Tris-tricine SDS PAGE gels and stained with Coomassie Brilliant Blue. Blue and red arrows are indicative of A β ₄₂ and LRP::FLAG respectively.

lacking recombinant LRP::FLAG expression (Fig. 2d). Furthermore, cell lysates in which LRP::FLAG was recombinantly expressed were analysed and column immobilization was confirmed (Fig. 2E). In addition, this control served to demonstrate the number of cellular components which were able to bind to LRP::FLAG (Fig. 2e). Fig. 2f, served to assess whether the “sticky” nature of A β ₄₂ allowed it to bind to the affinity column in the absence of the tagged protein. Upon analysis of 10 μ g of synthetic A β ₄₂, the peptide was present in the unbound soluble fraction (Fig. 2f, lane 2) thereby illustrating that the presence of A β ₄₂ in the eluted sample of the Fig. 2a, lane 5, was owing to an immobilizing interaction with LRP.

As an interaction between LRP/LR and A β ₄₂ has been proposed an investigation into the influence of such an interaction on AD pathogenesis, specifically cellular survival, was justifiable. Significant reductions in cellular viability across all three cell lines were observed at varying concentrations of exogenously administered synthetic A β ₄₂ (Fig. 3a–c). More notably, upon co-incubation of cells with the A β ₄₂ peptide and anti-LRP/LR specific antibody IgG1-iS18, a significant enhancement in cell viability was observed (Fig. 3a–c). These results were further confirmed by shRNA mediated down regulation of LRP/LR (Fig. 4c), thereby demonstrating that the cell rescuing abilities of IgG1-iS18 are not owing to a lack of antibody specificity. Thus, it may be suggested that LRP/LR may be implicated in A β mediated cytotoxicity and the association between these

proteins may be pathological in nature. It is plausible that this association may be pathological in nature as PrP^c has been reported to be important in mediating the synaptotoxic effects of A β ¹⁹ and the neuroprotective role of PrP^c may be inhibited upon its binding to A β . Thus both PrP^c and its cell surface receptor LRP/LR²⁵ may be implicated in mediating this pathological role.

Furthermore, to assess whether the impediment of cellular proliferation contributed to reduced cell viability (Fig. 3a–c), the proliferative potential of N2a cells incubated with varying A β ₄₂ concentrations was evaluated. Cellular proliferation was similarly hampered in the presence of A β ₄₂ and IgG1-iS18 (Fig. 3d) rescued cells from this effect. This result was further corroborated by enhancement in cellular proliferation observed when A β was administered to cells in which LRP/LR was down regulated by shRNAs (Fig. 4d). Therefore, it may be proposed that the LRP/LR-A β ₄₂ interaction may possibly result in aberrant proliferative cell signaling pathways. Under physiological conditions, LRP/LR promotes cellular survival, reported through the activation of the Mitogen activated protein (MAP) kinase signal transduction pathway³⁶. It is plausible that an interaction between LRP/LR and A β ₄₂ may foil the receptor mediated initiation of proliferative pathways.

In conclusion, it has been demonstrated that an LRP/LR-A β ₄₂ interaction occurred on the cell surface and antibody blockade of LRP/LR by IgG1-iS18 or shRNA mediated down regulation of LRP/LR




Figure 3 | Cell rescuing effects of anti-LRP/LR antibody IgG1-iS18. (a) Cellular viability of HEK293 cells, as determined by (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (1 mg/ml) assay, post exogenous treatment with synthetic A β_{42} and upon co-incubation with anti-LRP/LR IgG1-iS18 or IgG1-HD37 (negative control). The cell viability was assessed 48 h post treatment and the no antibody control was set to 100%. SH-SY5Y (b) and N2a cells (c) were exposed to similar treatments. (d) Cellular proliferation of N2a cells as determined by colorimetric 5-bromo-2'-deoxyuridine (BrdU) non-isotopic immunoassay (Calbiochem®), allowing 4 h for BrdU incorporation into cultured cells. Error bars represent sd. ** $p < 0.01$; Student's *t*-test.

LR rescued cells from A β_{42} induced cytotoxicity and impedence of proliferation. These results suggest that LRP/LR may contribute to A β_{42} mediated pathogenesis in AD and that anti-LRP/LR specific antibodies and shRNAs directed against the receptor mRNA may show promise in the quest for effective AD disease-modulating therapeutics.

Methods

Immunofluorescence Microscopy. HEK293FT and N2a cells were seeded onto microscope coverslips and incubated until a confluency of 50–70% was attained. The cells were subsequently fixed with 4% Paraformaldehyde (10 minutes, room temperature), rinsed thrice with 1xPBS and blocked in 0.5%PBS-BSA (5–10 minutes). Post blocking, coverslips were additionally washed in PBS and placed such that the cell-free side came into contact with the microscope slide. 100 μ l of primary antibody solution (diluted in 0.05%PBS-BSA) containing 1:150 IgG1-iS18 (human), 1:150 anti-VLA6 or 1:100 anti- β -amyloid (22–35) (rabbit (Sigma) was administered to the cells. Post an overnight incubation at 4°C in moist containers, coverslips were again washed thrice in 0.5% PBS-BSA and placed on clean slides. A 100 μ l volume of a secondary antibody solution containing 1:300 goat anti-human FITC (Cell Lab) and 1:300 goat anti-rabbit IgG conjugated to Alexa Fluor® 633 (Invitrogen) were administered to cells and incubated for an hour in the dark. Post incubation, coverslips were washed twice in 0.5% PBS-BSA and once in PBS and mounted onto clean microscope slides using 50 μ l Fluoromount (Sigma Aldrich). The Olympus IX71 Immunofluorescence Microscope and Analysis Get It Research Software were employed to detect fluorescence and acquire images, respectively. Images were analysed and 2D cytofluorograms were constructed using Cell Sens Software.

Pull down assay. HEK293 cells were transfected via calcium phosphate methodology with a pCIneo-LRP::FLAG plasmid for 72 hours at 37°C, 5% CO₂. Pull down experimental samples were composed of 200 μ l of HEK293 whole cell lysates in which LRP::FLAG was recombinantly expressed and 10–20 μ l of synthetic A β_{42} (Sigma-Aldrich) was exogenously administered. Assays were performed using FLAG® Immunoprecipitation Kit (Sigma-Aldrich) according to manufacturer's instructions. Samples were subsequently electrophoretically analysed and gels were stained with Coomassie Blue. LRP::FLAG was detected via immunoblotting using

murine anti-FLAG antibody (1:4000) (Sigma-Aldrich) and goat anti-mouse HRP (1:10 000) (Beckman Coulter).

3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell viability assay. HEK293, N2a and SH-SY5Y cells were seeded in a 96 well plate as to attain 50–70% confluency within 24 hours and incubated in a 5% CO₂ humidified atmosphere at 37°C. Post incubation, synthetic neurotoxic Amyloid beta (A β) peptide (Sigma Aldrich) was administered to the cells in varying concentrations (100 nM, 200 nM and 500 nM respectively) to determine the affect thereof on cell viability. In addition, untreated controls (cells incubated in DMEM) as well as positive controls (cells incubated with 8 mM protocatechuic acid(PCA)-an apoptosis inducing agent) were included. Furthermore, cells were additionally co-incubated with A β (at the concentrations listed above) as well as either 50 μ g/ml IgG1-iS18 antibody or 50 μ g/ml IgG1-HD37 antibody (Affimed Therapeutics). Treated cells were incubated (37°C, 5% CO₂) for 48 hours, following which 20 μ l of 1 mg/ml MTT was added to each well and the cells subsequently incubated (37°C, 5%CO₂) for 2 hours. After incubation, culture media was aspirated and 180 μ l of DMSO added to each well to lyse the cells and dissolve the formazan crystals formed within the cells. The absorbance was recorded at 570 nm using an ELISA microtiter plate reader and the percentage survival of the cells, relative to the non-treated controls, calculated. Three separate experiments were performed, each in triplicate.

Bromodeoxyuridine (BrdU) proliferation assay. HEK293, N2a and SH-SY5Y cells were seeded in a 96 well plate as to attain 50–70% confluency within 24 hours and incubated in a 5% CO₂ humidified atmosphere at 37°C. Post incubation, synthetic neurotoxic Amyloid beta (A β) peptide (Sigma Aldrich) was administered to the cells in varying concentrations (100 nM, 200 nM and 500 nM respectively) in the presence or absence of IgG1-iS18 or IgG1-HD37. Proliferative potential of treated cells was assessed as per manufacturer's instructions for BrdU Proliferation Assay Kit (Calbiochem®). Three separate experiments were performed, each in triplicate.

Production of shRNA directed against LRP/LR mRNA. shRNAs were designed to be expressed from the H1 RNA Pol III Promoter. shRNA1.1 was designed to be homologous to murine sequences reported in previous studies and shRNA7.6 was designed using The RNAi Consortium. The expression cassettes comprised of a full H1 RNA Pol III promoter sequence, a poly T termination signal and the guide strand on the 3' arm. The shRNA expression cassettes were generated using nested PCR in




Figure 4 | shRNA-mediated downregulation of LRP/LR and the effects thereof. (a) HEK293FT cells were transfected with shRNAsc, shRNA1.1 and shRNA7.6 using the *TransIT*[®]-LT1 Transfection reagent. 72 h post transfection total LRP/LR levels were assessed by Western blotting. β -actin was employed as a loading control. Gels have been cropped for clarity and conciseness purposes and have been run under the same experimental conditions. (b) Bar graph depicting percentage LRP/LR down regulation was generated by quantifying the Western blot band intensities of three independent experiments employing Quantity One 4.6 Software. To assess the role of LRP/LR in A β toxicity 24 h post transfection, varying concentrations of synthetic A β was exogenously administered to cells. 72 h post transfection (48 h post A β incubation) cellular viability was assessed by MTT assay (c) and cellular proliferation was assessed by BrdU assay (d) Error bars represent sd. *** $p < 0.001$; ** $p < 0.01$; * $p < 0.05$ Student's *t*-test.



which the H1 RNA Pol III promoter served as the template. The forward primer was complementary to that of the H1 RNA Pol III promoter and the shRNA sequences were incorporated into the reverse primers. The resultant PCR products, which coded for the shRNA expression constructs were subsequently cloned into the pTZ57R/T vector (Fermentas). An shRNA that does not target any gene, herein termed scrambled shRNA (shRNAsc), served as the negative control. The LRP/LR target sequence as well as the structure of shRNA1.1 and shRNA7.6 are described in Jovanovic et al., (2013)²⁷.

Cellular transfection with shRNA directed against LRP/LR mRNA. The TransIT[®]-LT1 Transfection reagent (Mirus) was employed to transfect LRP/LR shRNA 1 and 7 into HEK293 cells as per the manufacturer's instructions.

Western blotting. Post 72 h transfection of HEK293 cells with shRNAs, cells were lysed and total LRP/LR levels were determined by Western blotting employing IgG1-iS18 (1 : 10 000) and goat anti-human horseradish peroxidase (HRP) (1 : 10 000) (Cell Lab) antibodies, respectively. Western blot band intensities were quantified using Quantity One 4.6 Software.

Assessing cell viability and proliferation post cellular transfection with shRNA. Synthetic A β_{42} , at varying concentrations, was exogenously administered to transfected cells, 24 h post transfection. Thereafter cells were incubated in the presence of A β for an additional 48 h prior to analysis by MTT and BrdU assay respectively.

Statistical evaluation. Student's *t*-tests were used to analyse the data and obtain *p* values. All statistical evaluations were performed using GraphPad Prism (version 5.03) software.

- Verdier, Y. & Penke, B. Binding sites of amyloid beta-peptide in cell plasma membrane and implications for Alzheimer's disease. *Curr Protein Pept Sci* **5**, 19–31 (2004).
- Serrano-Pozo, A., Frosch, M. P., Masliah, E. & Hyman, B. T. Neuropathological alterations in Alzheimer disease. *Cold Spring Harb Perspect Med* **1**, a006189, doi:10.1101/cshperspect.a006189 (2011).
- Gonsalves, D., Jovanovic, K., Da Costa Dias, B. & Weiss, S. F. Global Alzheimer Research Summit: basic and clinical research: present and future Alzheimer research. *Prion* **6**, 7–10, doi:10.4161/pri.6.1.18854 (2012).
- Kakiya, N. et al. Cell surface expression of the major amyloid-beta peptide (A β)-degrading enzyme, neprilysin, depends on phosphorylation by mitogen-activated protein kinase/extracellular signal-regulated kinase (MEK) and dephosphorylation by protein phosphatase 1a. *J Biol Chem* **287**, 29362–29372, doi:10.1074/jbc.M112.340372 (2012).
- Jarrett, J. T., Berger, E. P. & Lansbury, P. T., Jr. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. *Biochemistry* **32**, 4693–4697 (1993).
- Saido, T. C. Alzheimer's disease as proteolytic disorders: anabolism and catabolism of beta-amyloid. *Neurobiol Aging* **19**, S69–75 (1998).
- Spires-Jones, T. L. et al. Impaired spine stability underlies plaque-related spine loss in an Alzheimer's disease mouse model. *Am J Pathol* **171**, 1304–1311, doi:10.2353/ajpath.2007.070055 (2007).
- Koffie, R. M. et al. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. *Proc Natl Acad Sci U S A* **106**, 4012–4017, doi:10.1073/pnas.0811698106 (2009).
- Hyman, B. T. et al. Quantitative analysis of senile plaques in Alzheimer disease: observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome). *Proc Natl Acad Sci U S A* **92**, 3586–3590 (1995).
- Mucke, L. & Selkoe, D. J. Neurotoxicity of Amyloid beta-Protein: Synaptic and Network Dysfunction. *Cold Spring Harb Perspect Med* **2**, a006338, doi:10.1101/cshperspect.a006338 (2012).
- Stefani, M. Biochemical and biophysical features of both oligomer/fibril and cell membrane in amyloid cytotoxicity. *FEBS J* **277**, 4602–4613, doi:10.1111/j.1742-4658.2010.07889.x (2010).
- Sepulveda, F. J., Parodi, J., Peoples, R. W., Opazo, C. & Aguayo, L. G. Synaptotoxicity of Alzheimer beta amyloid can be explained by its membrane perforating property. *PLoS One* **5**, e11820, doi:10.1371/journal.pone.0011820 (2010).
- Demuro, A. et al. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. *J Biol Chem* **280**, 17294–17300, doi:10.1074/jbc.M500997200 (2005).
- Lin, H., Bhatia, R. & Lal, R. Amyloid beta protein forms ion channels: implications for Alzheimer's disease pathophysiology. *FASEB J* **15**, 2433–2444, doi:10.1096/fj.01-0377.com (2001).
- Marchesi, V. T. Alzheimer's dementia begins as a disease of small blood vessels, damaged by oxidative-induced inflammation and dysregulated amyloid metabolism: implications for early detection and therapy. *FASEB J* **25**, 5–13, doi:10.1096/fj.11-0102ufm (2011).
- Bartzokis, G. Alzheimer's disease as homeostatic responses to age-related myelin breakdown. *Neurobiol Aging* **32**, 1341–1371, doi:10.1016/j.neurobiolaging.2009.08.007 (2011).

- Da Costa Dias, B., Jovanovic, K., Gonsalves, D. & Weiss, S. F. Structural and mechanistic commonalities of amyloid-beta and the prion protein. *Prion* **5**, 126–137, doi:10.4161/pri.5.3.17025 (2011).
- Li, S. et al. Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. *Neuron* **62**, 788–801, doi:10.1016/j.neuron.2009.05.012 (2009).
- Kudo, W. et al. Cellular prion protein is essential for oligomeric amyloid-beta-induced neuronal cell death. *Hum Mol Genet* **21**, 1138–1144, doi:10.1093/hmg/ddr542 (2012).
- Resenberger, U. K. et al. The cellular prion protein mediates neurotoxic signalling of beta-sheet-rich conformers independent of prion replication. *EMBO J* **30**, 2057–2070, doi:10.1038/emboj.2011.86 (2011).
- Parkin, E. T. et al. Cellular prion protein regulates beta-secretase cleavage of the Alzheimer's amyloid precursor protein. *Proc Natl Acad Sci U S A* **104**, 11062–11067, doi:10.1073/pnas.0609621104 (2007).
- Leucht, C. et al. The 37 kDa/67 kDa laminin receptor is required for PrP(Sc) propagation in scrapie-infected neuronal cells. *EMBO Rep* **4**, 290295–, doi:10.1038/sj.embo.embor768 (2003).
- Mbazima, V., Da Costa Dias, B., Omar, A., Jovanovic, K. & Weiss, S. F. Interactions between PrP(c) and other ligands with the 37-kDa/67-kDa laminin receptor. *Front Biosci* **15**, 1150–1163 (2010).
- Omar, A. et al. Patented biological approaches for the therapeutic modulation of the 37 kDa/67 kDa laminin receptor. *Expert Opin Ther Pat* **21**, 35–53, doi:10.1517/13543776.2011.539203 (2011).
- Gauczynski, S. et al. The 37-kDa/67-kDa laminin receptor acts as the cell-surface receptor for the cellular prion protein. *EMBO J* **20**, 5863–5875, doi:10.1093/emboj/20.21.5863 (2001).
- Hundt, C. et al. Identification of interaction domains of the prion protein with its 37-kDa/67-kDa laminin receptor. *EMBO J* **20**, 5876–5886, doi:10.1093/emboj/20.21.5876 (2001).
- Gauczynski, S. et al. The 37-kDa/67-kDa laminin receptor acts as a receptor for infectious prions and is inhibited by polysulfated glycanes. *J Infect Dis* **194**, 702–709, doi:10.1086/505914 (2006).
- Zuber, C. et al. Invasion of tumorigenic HT1080 cells is impeded by blocking or downregulating the 37-kDa/67-kDa laminin receptor. *J Mol Biol* **378**, 530–539, doi:10.1016/j.jmb.2008.02.004 (2008).
- Omar, A., Reusch, U., Knackmuss, S., Little, M. & Weiss, S. F. Anti-LRP/LR-specific antibody IgG1-iS18 significantly reduces adhesion and invasion of metastatic lung, cervix, colon and prostate cancer cells. *J Mol Biol* **419**, 102–109, doi:10.1016/j.jmb.2012.02.035 (2012).
- Khumalo, T. et al. Adhesion and Invasion of Breast and Oesophageal Cancer Cells Are Impeded by Anti-LRP/LR-Specific Antibody IgG1-iS18. *PLoS One* **8**, e66297, doi:10.1371/journal.pone.0066297 (2013).
- Khusal, R. et al. In vitro inhibition of angiogenesis by antibodies directed against the 37 kDa/67 kDa laminin receptor. *PLoS One* **8**, e58888, doi:10.1371/journal.pone.0058888 (2013).
- Kibbey, M. C. et al. beta-Amyloid precursor protein binds to the neurite-promoting IKVAV site of laminin. *Proc Natl Acad Sci U S A* **90**, 10150–10153 (1993).
- Lacor, P. N. et al. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. *J Neurosci* **24**, 10191–10200, doi:10.1523/JNEUROSCI.3432-04.2004 (2004).
- Manczak, M., Calkins, M. J. & Reddy, P. H. Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damage. *Hum Mol Genet* **20**, 2495–2509, doi:10.1093/hmg/ddr139 (2011).
- Venticinque, L., Jamieson, K. V. & Meruelo, D. Interactions between laminin receptor and the cytoskeleton during translation and cell motility. *PLoS One* **6**, e15895, doi:10.1371/journal.pone.0015895 (2011).
- Givant-Horwitz, V., Davidson, B. & Reich, R. Laminin-induced signaling in tumor cells: the role of the M(r) 67,000 laminin receptor. *Cancer Res* **64**, 3572–3579, doi:10.1158/0008-5472.CAN-03-3424 (2004).
- Jovanovic, J. et al. Anti-LRP/LR specific antibodies and shRNAs impede amyloid beta shedding in Alzheimer's disease. *Sci. Rep.* **3**, 2699; doi:10.1038/srep02699 (2013).

Acknowledgments

This work is based upon research supported by the National Research Foundation (NRF), the Republic of South Africa (RSA). Any opinions, findings and conclusions or recommendations expressed in this material are those of the author(s), and therefore, the National Research Foundation does not accept any liability in this regard thereto.

Author contributions

Conceived and designed the experiments: S.F.T.W. Design of shRNA: M.W. Performed experiments: B.D.C.D., D.G. and K.M. Assisted with the immunofluorescence microscopy: C.P. Antibody (IgG1-HD37) production: U.R., S.K. and M.L. Analysed data: B.D.C.D. Wrote the manuscript: B.D.C.D., K.J. and D.G. Edited the manuscript: B.D.C.D. and S.F.T.W.



Additional information

Supplementary information accompanies this paper at <http://www.nature.com/scientificreports>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Da Costa Dias, B. *et al.* Anti-LRP/LR specific antibody IgG1-iS18

and knock-down of LRP/LR by shRNAs rescue cells from A β ₄₂ induced cytotoxicity. *Sci. Rep.* **3**, 2702; DOI:10.1038/srep02702 (2013).



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported license. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/3.0>